Mesenchymal Stem Cell-Derived Extracellular Vesicles for Functional Intracellular Delivery: Engineering, Targeting, Cellular Uptake, Biological Barriers, and Therapeutic Translation
- 1Department of Medical Biochemistry, Faculty of Medicine, Kahramanmaraş Sütçü İmam University, Kahramanmaraş 46050, Türkiye
Abstract
Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) are considered promising biological carriers for biomolecule and drug delivery because of their inherent biological activities, biocompatibility, and capacity to carry a variety of therapeutic cargoes. However, the limited cargo-loading capacity of native EVs, their inefficient delivery to target cells, intracellular trafficking barriers, and limitations in the functional release of their cargo restrict their therapeutic applications. EV engineering encompasses a range of approaches to overcome these limitations, including donor cell modification, endogenous cargo loading and active sorting mechanisms, post-isolation loading methods, surface engineering, and EV–lipid-based hybrid systems. In this review, engineered MSC-EVs are evaluated in terms of cargo loading, targeting, cellular uptake, intracellular trafficking, and functional cargo delivery. We also compare the loading strategies used for nucleic acids, proteins, enzymes, and small molecules, in terms of their advantages, their limitations, and their effect on EV biological activity. The therapeutic applications of MSC-EV-based systems in cardiovascular diseases, wound healing, neurological and musculoskeletal disorders, inflammatory diseases, and cancer are evaluated. The central conclusion of this review is that the therapeutic efficacy of MSC-EVs depends not only on the amount of cargo delivered but also on its delivery to the appropriate target cells, intracellular targeting, and preservation of its biological activity. Accordingly, future EV engineering strategies should aim to simultaneously improve cargo loading, disease-specific targeting, local retention, and cargo stability. Progress on these four fronts is what would make MSC-EVs predictable enough for clinical use.
Related
- Therapeutic Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles for Tendon Regeneration: Insights into Inflammatory and Angiogenesis Modulation
- Small extracellular vesicle-enriched preparations derived from genetically modified multipotent mesenchymal stromal cells promote fibroblast proliferation and extracellular matrix remodeling in vitro
- Design and validation of a GMP-compliant manufacturing platform of extracellular vesicles from mesenchymal stromal cells
- Angiogenic Potential of Small Extracellular Vesicles Produced by Stimulated Mesenchymal Stromal Cells Under Hypoxic Conditions
- The cotyloid fossa fat pad as a hip-specific orthobiologic niche: lessons from the infrapatellar fat pad for mesenchymal stem/stromal cell and extracellular vesicle therapy in osteoarthritis
BibTeX
@article{uremis2026mesenchymal,
title = {{Mesenchymal Stem Cell-Derived Extracellular Vesicles for Functional Intracellular Delivery: Engineering, Targeting, Cellular Uptake, Biological Barriers, and Therapeutic Translation}},
author = {Nuray Üremiş and Muhammed Mehdi Üremiş},
journal = {Cells},
year = {2026},
month = oct,
doi = {10.3390/cells15211987},
url = {https://www.mdpi.com/2073-4409/15/21/1987},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Mesenchymal Stem Cell-Derived Extracellular Vesicles for Functional Intracellular Delivery: Engineering, Targeting, Cellular Uptake, Biological Barriers, and Therapeutic Translation
AU - Nuray Üremiş
AU - Muhammed Mehdi Üremiş
PY - 2026
DA - 2026/10/30
JO - Cells
DO - 10.3390/cells15211987
UR - https://www.mdpi.com/2073-4409/15/21/1987
AB - Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) are considered promising biological carriers for biomolecule and drug delivery because of their inherent biological activities, biocompatibility, and capacity to carry a variety of therapeutic cargoes. However, the limited cargo-loading capacity of native EVs, their inefficient delivery to target cells, intracellular trafficking barriers, and limitations in the functional release of their cargo restrict their therapeutic applications. EV engineering encompasses a range of approaches to overcome these limitations, including donor cell modification, endogenous cargo loading and active sorting mechanisms, post-isolation loading methods, surface engineering, and EV–lipid-based hybrid systems. In this review, engineered MSC-EVs are evaluated in terms of cargo loading, targeting, cellular uptake, intracellular trafficking, and functional cargo delivery. We also compare the loading strategies used for nucleic acids, proteins, enzymes, and small molecules, in terms of their advantages, their limitations, and their effect on EV biological activity. The therapeutic applications of MSC-EV-based systems in cardiovascular diseases, wound healing, neurological and musculoskeletal disorders, inflammatory diseases, and cancer are evaluated. The central conclusion of this review is that the therapeutic efficacy of MSC-EVs depends not only on the amount of cargo delivered but also on its delivery to the appropriate target cells, intracellular targeting, and preservation of its biological activity. Accordingly, future EV engineering strategies should aim to simultaneously improve cargo loading, disease-specific targeting, local retention, and cargo stability. Progress on these four fronts is what would make MSC-EVs predictable enough for clinical use.
SN - 2073-4409
ER -